Nikhil I. Khushalani

Also affiliated with Moffitt Cancer Center

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 18 papers. Top paper: “Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial”.

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02498-y

N/A

4.8DataRank · unranked

171 citations

Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia +28 more

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Neuro-Oncology(2021)10.1093/neuonc/noab094

N/A

4.0DataRank · unranked

126 citations

Peter Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid +18 more

Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

Pigment Cell & Melanoma Research(2020)10.1111/pcmr.12861

N/A

1.6DataRank · unranked

57 citations

Keiran S.M. Smalley, Priscilla K. Brastianos, Michael A. Davies, Ian E. McCutcheon, James K. Liu +13 more

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9501

N/A

1.3DataRank · unranked

18 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella +15 more

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

New England Journal of Medicine(2018)10.1056/nejmoa1805453

N/A

1.1DataRank · unranked

1335 citations

Peter A. Forsyth, Alain Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos +17 more

Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2103

N/A

0.571DataRank · unranked

44 citations

John E. Mullinax, Cheryl A. Cox, Amy M. Hall, Matthew Beatty, Jamie Blauvelt +18 more

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9502

N/A

0.464DataRank · unranked

21 citations

James Moon, Zeynep Eroglu, Siwen Hu‐Lieskovan, William E. Carson, David A. Wada +15 more

Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9507

N/A

0.434DataRank · unranked

17 citations

Julie E. Stein, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I. Khushalani +13 more

Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9511

N/A

0.239DataRank · unranked

3 citations

Janice M. Mehnert, Anita Giobbie‐Hurder, Kari Kendra, Gino K. In, April K.S. Salama +14 more

Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy

Cancer Discovery(2024)10.1158/2159-8290.cd-23-0798

N/A

0DataRank · unranked

25 citations

Yue Zhang, Oscar E. Ospina, Matt D. Nichols, Victoria A. Chu, Álvaro de Mingo Pulido +31 more

Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2768

N/A

0DataRank · unranked

11 citations

Zeynep Eroglu, Islam Eljilany, Jonathan S. Zager, R. Gonzalez, Amod A. Sarnaik +13 more

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0652

N/A

0DataRank · unranked

9 citations

Michael J. Shamblott, Andrew S. Brohl, Amod A. Sarnaik, Zeynep Eroglu, Nikhil I. Khushalani +13 more

Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600‐mutant melanoma

Cancer(2023)10.1002/cncr.35029

N/A

0DataRank · unranked

11 citations

Y. Ann Chen, Inna Smalley, Jiannong Li, Joseph Markowitz, Andrew S. Brohl +6 more

IFx-Hu2.0 phase I first in human study for unresectable melanoma for an intralesional “in-situ vaccine” approach.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e21542

N/A

0DataRank · unranked

6 citations

Michael J. Shamblott, Andrew S. Brohl, Amod A. Sarnaik, Zeynep Eroglu, Nikhil I. Khushalani +7 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0DataRank · unranked

102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response

Cancer Medicine(2021)10.1002/cam4.4138

N/A

0DataRank · unranked

13 citations

Robyn Panchaud, Elnara Muradova, Leah Cohen, James A. DeCaprio, Nikhil I. Khushalani +3 more

Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by IL-6 blockade

Research Square(2023)10.21203/rs.3.rs-3161761/v1

N/A

0DataRank · unranked

10 citations

Erez N. Baruch, Priyadahrshini Nagarajan, Frederico O. Gleber‐Netto, Xiayu Rao, Tongxin Xie +34 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more